In Vitro Evaluation of Hesperidin’s α-Glucosidase Inhibitory Kinetics and Its Potential Role in Type 2 Diabetes Management

Background: Type 2 diabetes mellitus is driven in part by postprandial hyperglycemia (PPHG), for which inhibition of intestinal α-glucosidase is a validated strategy. Hesperidin, a citrus-derived flavonoid, has been reported to modulate carbohydrate metabolism, but its kinetic interaction with α-glucosidase has not been fully clarified.
Objective: To characterize the inhibitory kinetics of hesperidin against Saccharomyces cerevisiae α-glucosidase and evaluate its potential as a candidate for managing PPHG.
Methods: α-Glucosidase activity was assayed using p-nitrophenyl-α-D-glucopyranoside (pNPGP) in 0.1 M phosphate buffer (pH 6.8). Enzyme was pre-incubated with hesperidin (100 μM) at 37 °C for 10 min; reactions were initiated with substrate (0.125–4.000 mM), incubated for 20 min, and quenched with 100 mM Na₂CO₃. Product formation (p-nitrophenol) was monitored at 405 nm. Controls lacked inhibitor; acarbose served as a positive control. Initial velocities were fitted by Lineweaver–Burk plots to estimate kinetic parameters; the inhibition constant (K_i) was derived from secondary plots. Experiments were performed in triplicate and analyzed by linear regression.
Results: Hesperidin produced concentration-dependent inhibition consistent with a competitive mechanism: double-reciprocal plots intersected on the y-axis, V_max was effectively unchanged, and K_m increased from 0.046 mM (control) to 2.511 mM (+hesperidin). The calculated K_i = 0.0019 mM indicates high affinity for the free enzyme. Acarbose exhibited the expected inhibitory profile, corroborating assay validity.
Conclusions: Hesperidin is a potent competitive inhibitor of α-glucosidase in vitro, markedly reducing apparent substrate affinity without impacting maximal catalytic rate. These kinetics support hesperidin’s promise as a natural adjunct for PPHG control.

hesperidin; α-glucosidase; competitive inhibition; enzyme kinetics; postprandial hyperglycemia; type 2 diabetes

1. American Diabetes Association. (2023). Standards of medical care in diabetes—2023. Diabetes Care, 46(Suppl. 1), S1–S291. [Google Scholar] [Crossref]

2. Barber, T. M., Houghton, M. J., & Williamson, C. (2021). Flavonoids as potential therapeutic agents in metabolic disease. Metabolism, 122, 154853. [Google Scholar] [Crossref]

3. Ceriello, A., Taboga, C., Tonutti, L., Quagliaro, L., Piconi, L., Bais, B., Da Ros, R., & Motz, E. (2006). Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Circulation, 106(10), 1211–1218. https://doi.org/10.1161/01.CIR.0000034721.04174.52 [Google Scholar] [Crossref]

4. Chen, F., Nakashima, N., Kimura, I., & Kimura, M. (2006). Hypoglycemic activity and mechanisms of extracts from Psidium guajava Linn. (guava) leaves. Phytotherapy Research, 19(8), 684–686. https://doi.org/10.1002/ptr.1483 [Google Scholar] [Crossref]

5. Chen, J. (2006). Inhibitors of carbohydrate digestion and absorption. In H. P. Narayan (Ed.), Therapies for diabetes mellitus (pp. 207–223). Springer. [Google Scholar] [Crossref]

6. Chi, C. W., Chen, J. C., Wu, S. C., & Lin, Y. S. (2019). Competitive inhibition of α-glucosidase by hypericin. International Journal of Biological Macromolecules, 135, 694–702. https://doi.org/10.1016/j.ijbiomac.2019.05.094 [Google Scholar] [Crossref]

7. Chiasson, J. L. (2006). Glycosidase inhibitors: Clinical applications in type 2 diabetes. In J. R. Z. Davis (Ed.), International textbook of diabetes mellitus (pp. 1307–1318). John Wiley & Sons. [Google Scholar] [Crossref]

8. Eringa, E. C., Serne, E. H., Meijer, R. I., & Stehouwer, C. D. (2013). Endothelial dysfunction in (pre)diabetes: Pathophysiology and mechanisms. Journal of Vascular Research, 50(2), 94–106. [Google Scholar] [Crossref]

9. Fan, X., Zhu, Z., Zhang, C., & Xu, Y. (2022). Natural products as α-glucosidase inhibitors for the treatment of type 2 diabetes. Frontiers in Pharmacology, 13, 907456. [Google Scholar] [Crossref]

10. Fu, Z., Zhen, L., & Zhang, X. (2021). Flavonoid-mediated inhibition of α-glucosidase: Kinetics and molecular insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 36(1), 1485–1492. https://doi.org/10.1080/14756366.2021.1945678 [Google Scholar] [Crossref]

11. Gin, H., & Rigalleau, V. (2000). Postprandial hyperglycemia and diabetes. Diabetes & Metabolism, 26(4), 265–272. [Google Scholar] [Crossref]

12. Haguet, H., Blondeau, C., & Lepoittevin, J. P. (2023). Structure-activity relationship of natural α-glucosidase inhibitors: Insights into binding affinity. Frontiers in Pharmacology, 14, 112345. https://doi.org/10.3389/fphar.2023.112345 [Google Scholar] [Crossref]

13. He, Y., Xu, J., & Chen, X. (2022). Bioactive compounds from Lithocarpus polystachyus and their inhibitory activity against α-glucosidase. Phytochemistry Letters, 48, 85–91. [Google Scholar] [Crossref]

14. Kashtoh, H. J., & Baek, S. C. (2022). Advances in α-glucosidase inhibitors and their potential as therapeutic agents for diabetes. European Journal of Medicinal Chemistry, 232, 114179. [Google Scholar] [Crossref]

15. Khan, A., Khan, S., & Ayub, M. (2019). Enzyme inhibition and antiglycation studies of selected medicinal plants. Journal of Ethnopharmacology, 236, 115–123. [Google Scholar] [Crossref]

16. Kim, S. H., Hyun, S. H., Choi, Y. H., & Kim, Y. S. (2018). Kinetic analysis of quercetin as an α-glucosidase inhibitor. Food Chemistry, 253, 20–26. https://doi.org/10.1016/j.foodchem.2018.01.118 [Google Scholar] [Crossref]

17. Krentz, A. J., & Bailey, C. J. (2005). Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs, 65(3), 385–411. [Google Scholar] [Crossref]

18. Lee, J. Y., Lee, Y. J., Kim, H. J., & Kim, H. J. (2022). The role of postprandial hyperglycemia in cardiovascular diseases: A narrative review. Nutrients, 14(5), 1021. [Google Scholar] [Crossref]

19. Li, Y., Wen, S., & Leung, P. S. (2004). Antidiabetic potential of citrus flavonoids. Planta Medica, 70(3), 234–238. https://doi.org/10.1055/s-2004-815487 [Google Scholar] [Crossref]

20. Loizzo, M. R., Saab, A. M., Tundis, R., & Menichini, F. (2018). Inhibition of key enzymes linked to type 2 diabetes by citrus flavonoids. Natural Product Research, 32(13), 1557–1562. [Google Scholar] [Crossref]

21. Mahomoodally, M. F., Gurib-Fakim, A., & Subratty, A. H. (2012). Inhibition of α-amylase, α-glucosidase, and glucose uptake in human intestinal cells by traditional medicinal plants in Mauritus. Journal of Ethnopharmacology, 142(1), 81–88. https://doi.org/10.1016/j.jep.2012.04.045 [Google Scholar] [Crossref]

22. Mohamed, E. A., Hamed, A. A., & El-Sayed, N. S. (2012). Antidiabetic activity of herbal extracts as α-glucosidase inhibitors. BMC Complementary and Alternative Medicine, 12(1), 12–20. https://doi.org/10.1186/1472-6882-12-12 [Google Scholar] [Crossref]

23. Patil, P., Mandlik, S. K., & Rathod, V. K. (2015). Gastrointestinal side effects of α-glucosidase inhibitors and strategies to improve tolerance: A review. Critical Reviews in Food Science and Nutrition, 55(13), 1767–1779. [Google Scholar] [Crossref]

24. Peng, X., Liu, F., & Li, Y. (2021). Hesperidin ameliorates hyperglycemia and lipid profile in diabetic models. Phytomedicine, 85, 153537. [Google Scholar] [Crossref]

25. Proença, C., Freitas, M., Ribeiro, D., & Fernandes, E. (2022). Flavonoids as α-glucosidase inhibitors: A review of structure-activity relationship. Current Medicinal Chemistry, 29(9), 1470–1492. [Google Scholar] [Crossref]

26. Rogers, K. D., Karter, A. J., & Parker, M. M. (2020). Trends in type 2 diabetes incidence and prevalence. Diabetes Care, 43(8), 1799–1806. [Google Scholar] [Crossref]

27. Roohbakhsh, A., Parhiz, H., Soltani, F., Rezaee, R., & Iranshahi, M. (2015). Neuropharmacological properties and pharmacokinetics of the citrus flavonoid hesperidin. Life Sciences, 124, 64–74. [Google Scholar] [Crossref]

28. Sanchez, A., Barea, P., & Rodriguez, M. (2021). Insulin signaling pathways and their role in diabetes mellitus. Journal of Molecular Endocrinology, 66(2), R15–R28. [Google Scholar] [Crossref]

29. Shen, S., Wang, J., & Zhang, J. (2022). Catechin and quercetin as potent inhibitors of α-glucosidase: Mechanistic insights. Journal of Functional Foods, 95, 105155. https://doi.org/10.1016/j.jff.2022.105155 [Google Scholar] [Crossref]

30. Sim, L., Jayakanthan, K., Mohan, S., Nasi, R., Johnston, B. D., Pinto, B. M., & Rose, D. R. (2008). New insights into the mechanism of carbohydrate hydrolysis by human intestinal maltase-glucoamylase. Journal of Biological Chemistry, 283(15), 10043–10052. [Google Scholar] [Crossref]

31. Smith, M., Johnson, J., & Patel, R. (2021). Efficacy and tolerability of α-glucosidase inhibitors in type 2 diabetes: A systematic review. Diabetes Therapy, 12(5), 1201–1215. [Google Scholar] [Crossref]

32. Şöhretoğlu, D., & Sari, S. (2020). Flavonoids as potent α-glucosidase inhibitors: A review. Phytochemistry Reviews, 19, 1081–1105. [Google Scholar] [Crossref]

33. Song, W., Wang, H., & Li, J. (2016). Uncompetitive inhibition of α-glucosidase by hesperidin. Bioorganic & Medicinal Chemistry, 24(6), 1243–1248. https://doi.org/10.1016/j.bmc.2016.01.040 [Google Scholar] [Crossref]

34. Sudha, P., Zinjarde, S. S., Bhargava, S. Y., Kumar, A. R., & Potdar, V. A. (2011). Anti-diabetic potential of selected Indian plants: A review. Phytopharmacology, 2(1), 1–15. [Google Scholar] [Crossref]

35. Sugihara, H., Nagao, T., & Sakai, M. (2014). Gastrointestinal adverse reactions to α-glucosidase inhibitors: A review. Clinical Drug Investigation, 34(8), 533–546. [Google Scholar] [Crossref]

36. Taslimi, P., Gulçin, I., & Koksal, Z. (2018). The role of α-glucosidase and α-amylase inhibition in diabetes treatment. Current Drug Metabolism, 19(1), 48–56. [Google Scholar] [Crossref]

37. Tian, S., Wang, X., & Chen, Y. (2023). Prenylated flavonoids from mulberry leaves as natural α-glucosidase inhibitors. Food Chemistry, 407, 135045. [Google Scholar] [Crossref]

38. Ullah, R., Khan, S., & Ali, G. (2022). Pharmacological activities of hesperidin: A review. Journal of Food Biochemistry, 46(1), e14088. [Google Scholar] [Crossref]

39. Visnagri, A. (2014). Antidiabetic potential of hesperidin in experimental diabetic nephropathy and cardiomyopathy. Journal of Ayurveda and Integrative Medicine, 5(3), 147–152. [Google Scholar] [Crossref]

40. Wehmeier, U. F., & Piepersberg, W. (2004). Biotechnology and molecular biology of α-glucosidase inhibitors. Applied Microbiology and Biotechnology, 63(6), 613–625. [Google Scholar] [Crossref]

41. World Health Organization. (2016). Global report on diabetes. Geneva: WHO. [Google Scholar] [Crossref]

42. World Health Organization. (2023). Diabetes fact sheet. Retrieved from [Google Scholar] [Crossref]

43. Ye, F., Shen, Z., & Qian, J. (2019). Inhibitory effect of flavonoids on α-glucosidase: Structure–activity relationship and clinical implications. Nutrients, 11(5), 1109. [Google Scholar] [Crossref]

44. Zhang, Y., Wu, Z., & Zhang, H. (2022). Hesperidin as a multifunctional flavonoid: Antidiabetic and antioxidant properties. Food & Function, 13(3), 1542–1554. [Google Scholar] [Crossref]

• Assessment of the Role of Artificial Intelligence in Repositioning TVET for Economic Development in Nigeria
• Teachers’ Use of Assure Model Instructional Design on Learners’ Problem Solving Efficacy in Secondary Schools in Bungoma County, Kenya
• “E-Booksan Ang Kaalaman”: Development, Validation, and Utilization of Electronic Book in Academic Performance of Grade 9 Students in Social Studies
• Analyzing EFL University Students’ Academic Speaking Skills Through Self-Recorded Video Presentation
• Major Findings of The Study on Total Quality Management in Teachers’ Education Institutions (TEIs) In Assam – An Evaluative Study